Precision Medicine in Oncology® | Specialty

Treating Advanced Medullary Thyroid Cancer

July 16th 2013

Multidisciplinary Treatment of Medullary Thyroid Cancer

July 16th 2013

Nonsurgical Treatment Options for Early-Stage MTC

July 16th 2013

Staging of Patients With Medullary Thyroid Cancer

July 16th 2013

Genetic Testing and Screening in Advanced MTC

July 16th 2013

Genetic Testing and Screening in Medullary Thyroid Cancer

July 16th 2013

Customizing Imaging Based on Calcitonin Levels in MTC

July 16th 2013

Introduction and Overview of MTC Diagnosis Challenges

July 16th 2013

Dr. Swain Discusses Studies From the 2013 ASCO Meeting

July 15th 2013

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, highlights information presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.

NCI Develops Large Dataset of Genomic Variants Across Nine Common Cancer Types

July 15th 2013

Researchers at the National Cancer Institute have developed a comprehensive analysis of coding variants in nine of the most frequently studied human tumor cell lines in cancer research.

FDA Approves Afatinib for Metastatic NSCLC

July 12th 2013

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

Dr. Tabernero on Molecular Characterization in GI Cancer

July 12th 2013

Josep Tabernero, MD, PhD, from the Vall d'Hebron University Hospital, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Research Spotlight: Promising Phase I Results

July 12th 2013

Highlights of key findings from several phase I clinical trials that provide insight into new and emerging druggable targets and targeted therapies.

Integrating Genetics and Genomics in GYN Patient Navigation

July 11th 2013

Cancer centers are beginning to establish oncology nurse navigator programs with integrated processes for assessment, identification, referral, education, care, and support for patients whose gynecologic cancers may be genetically-based.

Retrospective Analysis Confirms Poor Prognosis for Breast Cancer Patients With BRCA1 Mutations

July 11th 2013

Women with breast cancer who are carriers of BRCA1 mutations have increased mortality compared with noncarriers, according to a retrospective study carried out in the Netherlands.

Dr. Lenz Explores KRAS/NRAS Mutations in Colorectal Cancer

July 6th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

Big Moment for Nanotech: Oncology Therapeutics Poised for a Leap

July 2nd 2013

The translation of scientific advances in nanotechnology into cancer therapies, in vitro assays, and imaging tools is poised for takeoff, amid fresh excitement among investors and a mushrooming of findings from leading research institutions.

PARP Inhibitor Active in Recurrent BRCA-Mutant Ovarian Cancer

June 28th 2013

A dual-action PARP inhibitor has shown sufficient clinical activity to continue its investigation in women with recurrent BRCA-mutant ovarian cancer.

The Inflammation Link: NF-κB Remains a Difficult but Intriguing Target

June 28th 2013

The complex regulation of NF-κB activation has presented significant challenges for the development of anticancer agents, but researchers are now beginning to better understand and embrace this complexity to drive development of a variety of novel NF-κB-targeting strategies.

Dr. Seidman on Personalized and Precision Medicine

June 28th 2013

Andrew D. Seidman, MD, from the Memorial Sloan-Kettering Cancer Center, describes his excitement over the genetic advances made in the treatment of patients with cancer.